Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandated Part D Rebates Would Not Lead To Higher Premiums, Cost Shifts, MedPAC Commissioner Argues

This article was originally published in The Pink Sheet Daily

Executive Summary

In an online Health Affairs article, MedPAC commissioner Jack Hoadley and co-author Richard Frank rebut arguments against mandatory rebates on Medicare Part D drugs.

You may also be interested in...



Reimbursement News, In Brief

Some patient groups ask Congress not to consider Medicaid-style rebates for dual-eligibles and low-income subsidy recipients in Medicare Part D; 72% of office-based physicians are using electronic health records; disparities in Medicaid EHR adoption, based on allocation of incentive payments, mirror those found in Medicare EHR adoption.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns

Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.

Topics

UsernamePublicRestriction

Register

PS074868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel